Screener
Relmada Therapeutics, Inc. RLMD Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024. Open the filing →
- Filed
- Aug 7, 2024
- Fiscal quarter
- Q2 FY2024
- Calendar quarter
- Q2 2024
- Accession
- 0001213900-24-066111
FAQ
- What is Relmada Therapeutics, Inc.'s enterprise value?
- Relmada Therapeutics, Inc. (RLMD) reported enterprise value of $163.63M in Q2 2023.
- How has Relmada Therapeutics, Inc.'s enterprise value changed year-over-year?
- Relmada Therapeutics, Inc.'s enterprise value decreased by 76.9% year-over-year, from $706.96M to $163.63M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Relmada Therapeutics, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude